Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
Abstract: The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.
Type:
Application
Filed:
January 8, 2007
Publication date:
January 22, 2009
Applicant:
APOXIS SA
Inventors:
Virginie Petrilli, Fabio Martinon, Jurg Tschopp, Thibault De Smedt
Abstract: The invention concerns a method to prevent or reduce adverse effects on liver of a patient treated with a Fas-mediated apoptosis-inducing agent, the method comprising the administration of a product preventing TNF receptors-mediated apoptosis of the liver cells.
Type:
Application
Filed:
May 27, 2005
Publication date:
January 3, 2008
Applicant:
APOXIS SA
Inventors:
Marc Dupuis, Stephane Demotz, Rene Goedkoop
Abstract: A novel receptor in the TNF family is provided: APRIL-R. Chimeric molecules and antibodies to APRIL-R and methods of use thereof are also provided.
Abstract: The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.
Type:
Application
Filed:
October 9, 2006
Publication date:
July 12, 2007
Applicant:
APOXIS SA
Inventors:
Virginie Petrilli, Fabio Martinon, Jurg Tschopp, Thibaut De Smedt
Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.